110 related articles for article (PubMed ID: 2966671)
1. Schedule-dependent therapeutic gain from the combination of fractionated irradiation and cis-diamminedichloroplatinum (II) in C3H/Km mouse model systems.
Kanazawa H; Rapacchietta D; Kallman RF
Cancer Res; 1988 Jun; 48(11):3158-64. PubMed ID: 2966671
[TBL] [Abstract][Full Text] [Related]
2. Effects of fractionated schedules of irradiation combined with cis-diamminedichloroplatinum II on the SCCVII/St tumor and normal tissues of the C3H/KM mouse.
Tanabe M; Godat D; Kallman RF
Int J Radiat Oncol Biol Phys; 1987 Oct; 13(10):1523-32. PubMed ID: 3624028
[TBL] [Abstract][Full Text] [Related]
3. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo.
Mason KA; Kishi K; Hunter N; Buchmiller L; Akimoto T; Komaki R; Milas L
Clin Cancer Res; 1999 Dec; 5(12):4191-8. PubMed ID: 10632360
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic gain factors for fractionated radiation treatment of spontaneous murine tumors using fast neutrons, photons plus O2(1) or 3 ATA, or photons plus misonidazole.
Suit HD; Sedlacek R; Silver G; Hsieh CC; Epp ER; Ngo FQ; Roberts WK; Verhey L
Radiat Res; 1988 Dec; 116(3):482-502. PubMed ID: 3205910
[TBL] [Abstract][Full Text] [Related]
5. Schedule-dependent therapeutic gain from the combination of fractionated irradiation plus c-DDP and 5-FU or plus c-DDP and cyclophosphamide in C3H/Km mouse model systems.
Kallman RF; Rapacchietta D; Zaghloul MS
Int J Radiat Oncol Biol Phys; 1991 Feb; 20(2):227-32. PubMed ID: 1991683
[TBL] [Abstract][Full Text] [Related]
6. Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radioresponse.
Mason KA; Hunter NR; Raju U; Ariga H; Husain A; Valdecanas D; Neal R; Ang KK; Milas L
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1181-9. PubMed ID: 15234054
[TBL] [Abstract][Full Text] [Related]
7. Interaction of hyperthermia and cis-diamminedichloroplatinum(II) alone or combined with radiation in a C3H mammary carcinoma in vivo.
Overgaard J; Radacic MM; Grau C
Cancer Res; 1991 Jan; 51(2):707-11. PubMed ID: 1985787
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts.
Fan Z; Baselga J; Masui H; Mendelsohn J
Cancer Res; 1993 Oct; 53(19):4637-42. PubMed ID: 8402640
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine.
Grégoire V; Hunter N; Milas L; Brock WA; Plunkett W; Hittelman WN
Cancer Res; 1994 Jan; 54(2):468-74. PubMed ID: 8275483
[TBL] [Abstract][Full Text] [Related]
10. Increased therapeutic gain of combined cis-diamminedichloroplatinum (II) and whole body hyperthermia therapy by optimal heat/drug scheduling.
Baba H; Siddik ZH; Strebel FR; Jenkins GN; Bull JM
Cancer Res; 1989 Dec; 49(24 Pt 1):7041-4. PubMed ID: 2582445
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic enhancement in mice by clinically relevant dose and fractionation schedules of cis-diamminedichloroplatinum (II) and irradiation.
Bartelink H; Kallman RF; Rapacchietta D; Hart GA
Radiother Oncol; 1986 May; 6(1):61-74. PubMed ID: 3715061
[TBL] [Abstract][Full Text] [Related]
12. Lack of differential radiosensitization of hypoxic cells in a mouse tumor at low radiation doses per fraction by cisplatin.
Sun JR; Brown JM
Radiat Res; 1993 Feb; 133(2):252-6. PubMed ID: 8438067
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of cisplatin sensitivity of quiescent cells in solid tumors by combined treatment with tirapazamine and low-temperature hyperthermia.
Masunaga S; Ono K; Hori H; Akaboshi M; Kawai K; Suzuki M; Kinashi Y; Kasai S; Nagasawa H; Uto Y
Radiat Med; 1998; 16(6):441-8. PubMed ID: 9929144
[TBL] [Abstract][Full Text] [Related]
14. Antitumour activity of cis-diamminedichloroplatinum (II) against human tumour xenografts depends on its area under the curve in nude mice.
Kurihara N; Kubota T; Hoshiya Y; Otani Y; Watanabe M; Kumai K; Kitajima M
J Surg Oncol; 1996 Feb; 61(2):138-42. PubMed ID: 8606546
[TBL] [Abstract][Full Text] [Related]
15. Effect of acquired cisplatin resistance on the response of a xenografted human hypopharynx carcinoma to concurrent radiochemotherapy with cisplatin.
Jäckel M; Tausch-Treml R; Köpf-Maier P
Laryngoscope; 1994 Mar; 104(3 Pt 1):329-34. PubMed ID: 8127191
[TBL] [Abstract][Full Text] [Related]
16. Renal damage in mice after treatment with cisplatin and x-rays: comparison of fractionated and single-dose studies.
Stewart FA; Luts A; Oussoren Y; Begg AC; Dewit L; Bartelink H
NCI Monogr; 1988; (6):23-7. PubMed ID: 3352770
[TBL] [Abstract][Full Text] [Related]
17. Radiosensitizing effect of nicotinamide and carbogen combined in fractionated pions or x-rays in SCCVII tumors.
Ohizumi Y; Lam GK; Pickles T; Fryer C; Chaplin DJ
Radiat Med; 1995; 13(6):291-5. PubMed ID: 8850370
[TBL] [Abstract][Full Text] [Related]
18. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin.
Dorie MJ; Brown JM
Cancer Res; 1993 Oct; 53(19):4633-6. PubMed ID: 8402639
[TBL] [Abstract][Full Text] [Related]
19. Kinetics and mechanism of the 1-beta-D-arabinofuranosylcytosine-induced potentiation of cis-diamminedichloroplatinum(II) cytotoxicity.
Vadi H; Drewinko B
Cancer Res; 1986 Mar; 46(3):1105-9. PubMed ID: 3080232
[TBL] [Abstract][Full Text] [Related]
20. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
